Navigation Links
Hooper Holmes' Heritage Labs Division to Manufacture Biospecimen Kits for the National Children's Study
Date:10/21/2008

Heritage Labs Awarded Multi-Year Contract from Westat

BASKING RIDGE, N.J., Oct. 21 /PRNewswire-FirstCall/ -- Hooper Holmes (Amex: HH) today announced that its Heritage Labs division was awarded a contract to manufacture biospecimen kits for the National Children's Study (NCS) by Westat, an employee-owned corporation providing research services to agencies of the U.S. Government as well as businesses, foundations, and state and local governments. This component of the NCS was awarded to Westat by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under contract number HHSN275200503395C.

Mandated by Congress in the Children's Health Act of 2000, the NCS is a collaborative effort involving many public and private partners committed to improving children's health. The Study is led by a consortium of federal agencies including: the U.S. Department of Health and Human Services (the NICHD and the National Institute of Environmental Health Sciences within the NIH, and the Centers for Disease Control and Prevention) and the U.S. Environmental Protection Agency.

The NCS is a major longitudinal cohort study that will follow children from before birth to at least 21 years of age and will evaluate the effects of a variety of environmental factors, including chemical, physical, biological, and psychosocial factors, on children's health and well-being. Researchers will analyze how these elements interact with each other and what helpful and/or harmful effects they might have on children's health. Data will be collected from children and their families from different areas of the country, from varied backgrounds, and of different family types.

"We are proud to have been selected as the sole provider for one of the key elements to this monumental study," said Mark Patterson, President of Heritage Labs. "As the study progresses, Heritage Labs will gradually increase the volume of kits manufactured to coincide with the number of factors examined as the children grow older. This contract further strengthens our leadership position in lab testing and medical manufacturing."

The contract has an initial value of about $3 million over three years and may be extended.

In order to study the main hypotheses for the National Children's Study, a variety of data will be collected from participants, including biological specimens. Biospecimens from a potential mother, father, and/or child will either be collected by a data collector or self collected by the participant and will take place at defined time periods or visits during the study. The visits are defined as Pre-Pregnancy (P1), First Trimester Pregnancy (T1), Third Trimester Pregnancy (T3), Birth (B) and 1 month, 3 months, 6 months, or 12 months after the child is born.

In order to guarantee consistency of data collection across study locations and between participants, Heritage Labs will manufacture biospecimen collection kits that will help to streamline biospecimen collection and ensure efficiency, effectiveness, and good quality control in the field.

About Heritage Labs

Heritage Labs International LLC, a division of Hooper Holmes, was founded in 1997 as the value leader in laboratory services that provide information to help people manage and reduce risk. One of the most automated testing laboratories in the industry, Heritage Labs has achieved certification from the College of American Pathologists (CAP), a recognized benchmark of quality. All kit manufacturing and laboratory testing is performed at Heritage Labs' headquarters in Olathe, Kansas.

About Hooper Holmes

Hooper Holmes is the leader in collecting personal health data and transforming it into useful information, enabling customers to take actions that manage or reduce their risks and expenses. As the leading provider of risk assessment services for the insurance industry, Hooper Holmes provides insurers with the widest range of medical exam, data collection, laboratory testing and underwriting services in the industry.

With presence in over 250 markets and a network of thousands of examiners, Hooper Holmes can arrange a medical exam anywhere in the U.S. and deliver the results to its customers. Each year we arrange more medical exams than any other company and process 3.8 million specimens in our laboratory. We provide a complete service for wellness, disease management, and managed care companies including scheduling support, fulfillment of supplies, blood collection kits, medical screenings, lab testing and data transmission. We underwrite 300,000 cases annually and complete more than two million telephone interviews.

This press release contains "forward-looking" statements, as such term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the Company's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions. Among the important factors that could cause actual results to differ materially from those expressed in, or implied by, these forward-looking statements are our ability to successfully implement our business strategy; uncertainty as to our working capital requirements over the next 12 to 24 months; our ability to maintain compliance with the financial covenants in our credit facility; our expectations regarding our operating cash flows; and the rate of life insurance application activity. Additional information about these and other factors that could affect the Company's business is set forth in the Company's annual report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission on March 17, 2008. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this press release to reflect the occurrence of unanticipated events, except as required by law.


'/>"/>
SOURCE Hooper Holmes
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hooper Holmes Names Richard Whitbeck President of Portamedic Division
2. Hooper Holmes Announces Sale of Claims Evaluation Division
3. Hooper Holmes Announces First Quarter 2008 Results
4. Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman
5. Hooper Holmes Announces Fourth Quarter Earnings Release Date and Conference Call Information
6. Hooper Holmes to Provide Business Update
7. Hooper Holmes Updates Guidance
8. Hooper Holmes Marks 50,000 Health and Wellness Screenings
9. Hooper Holmes Announces Third Quarter 2007 Results
10. Hooper Holmes Appoints Leslie Hudson, PhD, to Board of Directors
11. Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: